Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study on Immunotherapy Enhancement Strategies for Muscle-invasive Bladder Cancer
NCT07717242Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sitagliptin, zeprumetostat, tafolecimab and ursodeoxycholic acid in bladder urothelial carcinoma (4 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Clinical Complete Response Rate at 18 weeks. Started Jul 2026; status: recruiting.
02
Drugs
sitagliptinzeprumetostattafolecimabursodeoxycholic acid
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT07717242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717242.